Clinical Trials Browser

Withdrawn × INDUSTRY × tebentafusp × Clear all

NCT02535078 2024-07-24

Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma

Phase 1/2 Withdrawn

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma